EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

NEW YORK, April 22, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

http://www.reportlinker.com/p01163175/EpiCast-Report-Non-Small-Cell-Lung-Cancer-NSCLC---Epidemiology-Forecast-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

Summary

This forecast was built on an in-depth analysis of historical trends for lung cancer incidence, mortality, and survival; smoking prevalence, disease stage at diagnosis, and the status of lung cancer screening programs in each market.

GlobalData epidemiologists forecast that the number of incident cases of NSCLC in the 9MM will grow from 1.03 million cases in 2012 to 1.26 million by 2022 at a rate of 2.2% per year. The increase in the number of NSCLS incident cases is driven by changes in the incidence of lung cancer, an aging population, population growth, smoking habits in men and women, and exposure to environmental risk factors. Of the nine markets, China will have the highest number of incident cases of NSCLC, growing from 0.55 million cases in 2012 to 0.69 million by 2022 at a rate of 2.5% per year. In addition to China, India and Japan are also important markets for NSCLC in the next 10 years because these countries have a growing older population, a high smoking prevalence, and few smoking bans compared with western countries.

Scope

- It also includes a 10-year epidemiology forecast of the diagnosed incident cases of NSCLC in these markets from 2012–2022.

- The incident cases are further segmented by sex and age (40–49 years, 50–59 years, 60–69 years, 70–79 years, and at ages 80 years and older), cancer stage at diagnosis (AJCC Stage I-IV), cancer histological subtype (adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others), and the proportion of smokers among NSCLC cases.

Reasons to buy

- Quantify patient populations in the global NSCLC market to improve product development, pricing, and launch plans.

- Organize sales and marketing efforts by identifying sex, age groups, and cancer histological subtypes that present the best opportunities for NSCLC therapeutics in each of the markets covered.

Table of Contents

1.1 List of Tables 5

1.2 List of Figures 5

2 Introduction 7

2.1 Catalyst 7

2.2 Upcoming Reports 7

3 Epidemiology 8

3.1 Risk Factors and Comorbidities 9

3.1.1 Smokers are more likely to have lung cancer than non-smokers 10

3.1.2 Long-term exposure to radon increases the risk of lung cancer 11

3.1.3 Family history of any cancer increases lung cancer risk 11

3.1.4 TB increases the risk of lung cancer and increases mortality risk 12

3.1.5 COPD is a comorbidity that reduces lung cancer survival 12

3.1.6 Lung cancer screening programs may not be beneficial 13

3.1.7 Stage at diagnosis significantly impacts the survival of lung cancer cases 14

3.2 Global Trends 14

3.2.1 US 18

3.2.2 France 22

3.2.3 Germany 24

3.2.4 Italy 25

3.2.5 Spain 27

3.2.6 UK 29

3.2.7 Japan 30

3.2.8 China 32

3.2.9 India 34

3.3 Forecast Methodology 35

3.3.1 Sources Used 37

3.3.2 Sources Not Used 41

3.3.3 Forecast Methods and Assumptions 42

3.4 Epidemiology Forecast (2012–2022) 44

3.4.1 Incident Cases of NSCLC 44

3.4.2 Age-Specific Incident Cases of NSCLC 46

3.4.3 Sex-Specific Incident Cases of NSCLC 47

3.4.4 Age-Standardized Incidence Rates of NSCLC 48

3.4.5 Segmentation of NSCLC Incident Cases 50

3.5 Discussion 58

3.5.1 Limitations of the Analysis 59

3.5.2 Strengths of the Analysis 59

4 Appendix 61

4.1 Bibliography 61

4.2 About the Authors 69

4.2.1 Epidemiologists 69

4.2.2 Reviewers 70

4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 71

4.2.4 Global Head of Healthcare 71

4.3 About GlobalData 72

4.4 About EpiCast 72

4.5 Contact Us 72

4.6 Disclaimer 73

List of Tables

Table 2: 9MM, Age-Standardized (World) Smoking Prevalence, Men and Women, 2006 and 2009 17

Table 3: 9MM, Sources of NSCLC Incidence Data 36

Table 4: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012–2022 44

Table 5: 9MM, Incident Cases of NSCLC, by Age, Men and Women, N (Row %), 2012 46

Table 6: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N (Row %), 2012 47

Table 7: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, N (Row %), 2012 51

Table 8: 9MM, Incident Cases of NSCLC, by Histological Subtype, Ages ?40 Years, Men and Women, N (Row %) , 2012 54

Table 9: Comparison of GlobalData Forecast for Lung Cancer Incident Cases with Globocan 2008 60

List of Figures

Figure 2: 9MM, Age-Standardized (World) Lung Cancer Incidence, Women Ages ?40 Years, 1993–2002 16

Figure 3: Age-Standardized (US 2000) Lung Cancer Incidence and Mortality, Men and Women, All Ages, US, 1999–2008 19

Figure 4: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, US, 1993–2008 20

Figure 5: Relative Risk of Death from Lung Cancer in Current Smokers, Men and Women, US 21

Figure 6: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, France, 1993–2008 23

Figure 7: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Germany, 1993–2008 24

Figure 8: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Italy, 1993–2008 26

Figure 9: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Spain, 1991–2007 28

Figure 10: Age-Standardized (World) Lung Cancer Incidence and Mortality, Ages ?40 Years, UK, 1993–2008 29

Figure 11: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, Japan, 1993–2008 31

Figure 12: Age-Standardized (World) Lung Cancer Incidence and Mortality, Men and Women Ages ?40 Years, China, 1993–2008 33

Figure 13: Age-Standardized (World) Lung Cancer Incidence, Men and Women Ages ?40 Years, India, 1993–2002 34

Figure 14: 9MM, Incident Cases of NSCLC, Men and Women Ages ?40 Years, N, Selected Years 2012–2022 45

Figure 15: 9MM, Incident Cases of NSCLC, by Sex, Ages ?40 Years, N, 2012 48

Figure 16: 9MM, Age-Standardized (World) NSCLC Incidence, 2012 49

Figure 17: 9MM, Incident Cases of NSCLC, by Stage at Diagnosis, Men and Women Ages ?40 Years, % and N, 2012 52

Figure 18: 9MM, Incident Cases of NSCLC by Histological Subtype, Men and Women Ages ?40 Years, %, 2012 55

Figure 19: 9MM, Proportion of Smokers Among NSCLC Cases and the General Population, Men and Women, %, 2012 56

Figure 20: Smoking History in NSCLC Cases in the 9MM, Men and Women Ages ?40 Years, N, 2012 57

To order this report:Pathology Industry: EpiCast Report: Non-Small Cell Lung Cancer (NSCLC) - Epidemiology Forecast to 2022

Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker